No Data
No Data
Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
This week, Pfizer Inc (NYSE:PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V. (NASDAQ:MYNZ) applied for Breakthrough Device Designation to the US Food and Drug Administration (FDA) for its revolutionary colorectal cancer (CRC) screening test, which subject to the review, would significantly accelerate the approval process.
Top Premarket Decliners
LegalZoom.com (LZ) shares plunged 28% in recent Wednesday premarket activity after JPMorgan downgraded the company to neutral from overweight and cut its price target to $9 from $14. JMP Securities
Mainz Biomed Seeks FDA Breakthrough Device Status for Colorectal Cancer Test
Top Premarket Gainers
Pineapple Energy (PEGY) shares climbed more than 67% in recent Tuesday premarket activity, a day after the company said it engaged Conduit Capital for structural internal support, staffing, and
Express News | Mainz Biomed Shares Are Trading Higher After the Company Announced the Submission for FDA Breakthrough Device Designation for Its CRC Screening Test
Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Shares of Mainz Biomed N.V. (NASDAQ:MYNZ) rose sharply in today's pre-market trading after the company announced submission for the FDA Breakthrough Device Designation for its next generation CRC
No Data
103389013 : This stock become trash now. Nobody care bout.
103389013 : Volume coming
Tan Yean TatOP : where?
103389013 : Just a little bit. Slowly will come I think
103389013 : See. Got some move already.